AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.
AMY-101 can induce a long-lasting anti-inflammatory effect.
AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.
AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis.
Animal Model: |
Fifteen adult male cynomolgus monkeys (Macaca fascicularis) (7-15 years old; 5.0-7.6 kg body weight). |
Dosage: |
0.1 mg/site; 50 μL of 2 mg/mL solution. |
Administration: |
Injected locally. (Either three times per week or once a week for 6 weeks followed by a 6-week follow-up period without treatment.) |
Result: |
Does not cause irritation in healthy gingiva. |
Animal Model: |
UUO and sham-operated mice. |
Dosage: |
1 mg/kg. |
Administration: |
Subcutaneous injection every 12 h, daily, 7 or 14 days. |
Result: |
1 mg/kg Cp40 had much less severe interstitial fibrosis than control peptide-injected mice. |